We are proud to share Galderma’s record-breaking results from the first quarter of 2024, and our first as a publicly listed company. For the first time in our history, we surpassed $1 billion in sales in the first three months of the year. This growth was delivered thanks to strong performances in all regions and all categories, especially injectable aesthetics, driven by executing on our proven Integrated Dermatology Strategy. Achieving this milestone demonstrates our steadfast commitment both to our growth journey and to delivering solutions that meet the needs of healthcare professionals, consumers and patients. It is also testament to the dedication of Galderma’s teams across the world.
Six products from Galderma’s portfolio of premium brands were recently designated as 2024 NewBeauty Award winners. The wins, ranging from our solutions in Dermatological Skincare and treatments in Injectable Aesthetics, underscore our strategy to leverage the latest in science to advance dermatology for every skin story: - Restylane® Eyelight won Best Filler for Under-Eye Hollows - Restylane® Kysse won Best Filler for Fuller Lips - Sculptra® won Best Collagen-Stimulating Injectable - ALASTIN® Skincare C-RADICAL Defense Antioxidant Serum won Best Vitamin C Serum - Cetaphil® Gentle Skin Cleanser won Best Cleanser for Sensitive Skin - Differin Acne Clearing Body Wash won Best Body Wash for Acne-Prone Skin NewBeauty Award winners are handpicked via a rigorous and demanding selection process. A panel of industry experts, doctors and magazine editors sort through thousands of submissions to identify the best of the best. In fact, products and treatments undergo over six months of meticulous screening, including 200 hours of use and multiple rounds of testing and analysis. It’s an honor to be recognized by a title that’s trusted by both consumers and industry peers alike. Thank you to NewBeauty for the recognition!
